Skip to content
How It Works
Explore
Ask a Question Resources Pricing
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 15 peer-reviewed journal articles Updated
Hepatology

Building Your Care Team: Treatment and Management

At a Glance

Reynolds syndrome treatment requires a coordinated approach between a hepatologist and a rheumatologist. The primary goal is to protect the liver using medications like UDCA, while simultaneously managing systemic sclerosis symptoms like Raynaud's phenomenon and esophageal reflux.

Managing Reynolds syndrome requires a “dual-track” approach. Because it involves two different systems—your liver and your connective tissues—your care is most effective when it is coordinated between experts in Hepatology (liver) and Rheumatology (autoimmune/connective tissue) [1][2].

While it may feel like you are managing two separate diseases, the goal of your care team is to treat you as a whole person, using a multidisciplinary approach to balance the needs of both conditions [3].

Treating the Liver (PBC)

The primary goal of liver treatment is to protect your bile ducts and prevent liver scarring.

  • First-Line Therapy (UDCA): Ursodeoxycholic acid (UDCA) is the standard “baseline” medication [4]. It is a naturally occurring bile acid that helps move bile through the liver, reducing inflammation and significantly improving long-term survival [1][5].
  • Second-Line Options: If your liver enzymes (specifically Alkaline Phosphatase or ALP) do not reach target levels on UDCA alone, your doctor may add second-line treatments like obeticholic acid (OCA) or fibrates [6][7].
  • Managing Itching: For severe itching (pruritus), newer medications like seladelpar can provide relief [8][9]. Lifestyle Tip: Use cooling lotions (such as those containing menthol), avoid hot baths or showers, and wear soft, breathable fabrics to soothe your skin.
  • Managing Fatigue: Fatigue is complex. Pacing your daily activities, optimizing sleep habits, and having your doctor check for other causes (like vitamin deficiencies or thyroid issues) are critical for managing this symptom [10].

Managing Systemic Symptoms (SSc/CREST)

Treatment for the systemic sclerosis component focuses on managing individual symptoms to maintain your mobility and comfort.

  • Vascular Care: To manage Raynaud’s phenomenon, doctors often prescribe vasodilators such as calcium channel blockers (e.g., nifedipine, amlodipine) or PDE5 inhibitors (e.g., sildenafil) to help keep blood vessels open [11][12]. Lifestyle Tip: Wear thermal gloves and socks, avoid sudden temperature shifts, and use hand warmers during the winter months.
  • Digestive Health: Esophageal reflux and “slow” digestion are common. These are typically managed with Proton Pump Inhibitors (PPIs) and small, frequent meals [13].
  • Physical Function: To combat sclerodactyly (skin tightening on the fingers), specialized physical therapy and home-based exercise programs are essential for keeping your joints flexible [14][15].

Building Your “Dream Team”

Since Reynolds syndrome is rare, you need a care team that values collaboration. A typical team includes:

  1. The Hepatologist: Monitors your liver enzymes, performs periodic imaging (like a Fibroscan), and manages your PBC medications [1].
  2. The Rheumatologist: Manages the systemic sclerosis symptoms, monitors for vascular changes, and screens for potential lung or heart involvement [2].
  3. Specialist Support: Depending on your symptoms, you may also see a Gastroenterologist (for swallowing issues) or a Physical Therapist (for hand mobility) [13][15].

A Patient’s Role: With multiple specialists, you may need to act as the “coordinator” of your own care. Always request copies of your lab results and clinic notes, and ensure your Hepatologist and Rheumatologist are receiving updates from one another. Learn more about your Long-Term Outlook.

Common questions in this guide

How is Reynolds syndrome treated?
Because Reynolds syndrome involves both the liver and connective tissues, treatment uses a dual-track approach. You will likely take medications like UDCA for your liver, alongside therapies to manage systemic sclerosis symptoms like Raynaud's phenomenon and digestive issues.
Which doctors treat Reynolds syndrome?
Care is typically managed by a multidisciplinary team led by a hepatologist for the liver condition and a rheumatologist for the autoimmune issues. Depending on your specific symptoms, your team may also include a gastroenterologist or a physical therapist.
How will my doctor know if my liver treatment is working?
Your hepatologist will monitor your liver enzymes, specifically Alkaline Phosphatase (ALP). If your ALP does not reach target levels on standard medications, they may add second-line treatments like obeticholic acid or fibrates to better protect your liver.
What can I do to manage Raynaud's phenomenon symptoms?
Doctors often prescribe vasodilators, such as calcium channel blockers, to help keep blood vessels open. You can also manage triggers by wearing thermal gloves, avoiding sudden temperature shifts, and using hand warmers during the winter months.
How can I manage fatigue associated with Reynolds syndrome?
Fatigue is a complex symptom that requires comprehensive management. You should pace your daily activities, optimize your sleep habits, and have your doctor check for other underlying causes like vitamin deficiencies or thyroid issues.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.How will you and my rheumatologist/hepatologist coordinate my care? Who is the "lead" for my Reynolds syndrome?
  2. 2.How much experience do you have managing overlap syndromes like this?
  3. 3.What are the target numbers for my Alkaline Phosphatase (ALP) to know if the UDCA is working?
  4. 4.At what point would we consider adding a second-line treatment like obeticholic acid or a fibrate?
  5. 5.Are there specific medications I should avoid for my Raynaud's that might affect my liver?
  6. 6.How can we systematically manage my fatigue levels?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (15)
  1. 1

    Treatment of Primary Biliary Cholangitis including Transplantation.

    Muzahim Y, Wakil A, Bassi M, Pyrsopoulos N

    Clinics in liver disease 2024; (28(1)):103-114 doi:10.1016/j.cld.2023.07.003.

    PMID: 37945152
  2. 2

    Overlap syndrome of primary biliary cholangitis and primary sclerosing cholangitis: two case reports.

    Yacoub H, Ben Azouz S, Hassine H, et al.

    Journal of medical case reports 2023; (17(1)):169 doi:10.1186/s13256-023-03908-y.

    PMID: 37106413
  3. 3

    Systemic sclerosis and primary biliary cholangitis: a systematic review of case-control studies comparing isolated and overlapping disease phenotypes.

    Nursoy M, Mehmetoglu E, Syal A, et al.

    Journal of scleroderma and related disorders 2026; (11(1)):e000002 doi:10.1136/jsrd-2026-000002.

    PMID: 42256626
  4. 4

    Drug Therapies for Chronic Cholestatic Liver Diseases.

    Wagner M, Fickert P

    Annual review of pharmacology and toxicology 2020; (60()):503-527 doi:10.1146/annurev-pharmtox-010818-021059.

    PMID: 31506007
  5. 5

    Cholestatic liver diseases: new targets, new therapies.

    Santiago P, Scheinberg AR, Levy C

    Therapeutic advances in gastroenterology 2018; (11()):1756284818787400 doi:10.1177/1756284818787400.

    PMID: 30159035
  6. 6

    Combination of fibrates with obeticholic acid is able to normalise biochemical liver tests in patients with difficult-to-treat primary biliary cholangitis.

    Soret PA, Lam L, Carrat F, et al.

    Alimentary pharmacology & therapeutics 2021; (53(10)):1138-1146 doi:10.1111/apt.16336.

    PMID: 33764590
  7. 7

    Obeticholic Acid and Fibrates in Primary Biliary Cholangitis: Comparative Effects in a Multicentric Observational Study.

    Reig A, Álvarez-Navascués C, Vergara M, et al.

    The American journal of gastroenterology 2021; (116(11)):2250-2257 doi:10.14309/ajg.0000000000001343.

    PMID: 34158466
  8. 8

    Long-Term Efficacy and Safety of Selective PPARδ Agonist Seladelpar in Primary Biliary Cholangitis: ASSURE Interim Study Results.

    Levy C, Trivedi PJ, Kowdley KV, et al.

    The American journal of gastroenterology 2025; doi:10.14309/ajg.0000000000003603.

    PMID: 40553148
  9. 9

    Seladelpar efficacy and safety at 3 months in patients with primary biliary cholangitis: ENHANCE, a phase 3, randomized, placebo-controlled study.

    Hirschfield GM, Shiffman ML, Gulamhusein A, et al.

    Hepatology (Baltimore, Md.) 2023; (78(2)):397-415 doi:10.1097/HEP.0000000000000395.

    PMID: 37386786
  10. 10

    Advancing the management of primary biliary cholangitis: From pathogenesis to emerging therapies.

    Curto A, Iamello RG, Lynch EN, Galli A

    World journal of clinical cases 2025; (13(30)):109028 doi:10.12998/wjcc.v13.i30.109028.

    PMID: 41113084
  11. 11

    Aminaphtone Efficacy in Primary and Secondary Raynaud's Phenomenon: A Feasibility Study.

    Ruaro B, Pizzorni C, Paolino S, et al.

    Frontiers in pharmacology 2019; (10()):293 doi:10.3389/fphar.2019.00293.

    PMID: 31019461
  12. 12

    Management of Raynaud's phenomenon in systemic sclerosis-a practical approach.

    Fernández-Codina A, Cañas-Ruano E, Pope JE

    Journal of scleroderma and related disorders 2019; (4(2)):102-110 doi:10.1177/2397198318823951.

    PMID: 35382396
  13. 13

    Autoantibody predictors of gastrointestinal symptoms in systemic sclerosis.

    Ahmed F, Maclean RH, Nihtyanova SI, et al.

    Rheumatology (Oxford, England) 2022; (61(2)):781-786 doi:10.1093/rheumatology/keab395.

    PMID: 33909895
  14. 14

    Efficacy of Fractional CO2 Laser for Improvement of Limited Mouth Opening in Systemic Sclerosis.

    Bhat YJ, Bashir Y, Latif I, et al.

    Journal of cutaneous and aesthetic surgery 2022; (15(4)):387-393 doi:10.4103/JCAS.JCAS_29_21.

    PMID: 37035592
  15. 15

    Fractional Carbon Dioxide Laser for the Treatment of Microstomia in Limited-Cutaneous Systemic Sclerosis.

    Fisher C, Woodside SS, Martin YE, et al.

    Lasers in surgery and medicine 2025; (57(8)):658-662 doi:10.1002/lsm.70057.

    PMID: 40836485

This page provides information about Reynolds syndrome management for educational purposes only. Always consult your hepatologist and rheumatologist for medical advice and treatment plans specific to your condition.

Get notified when new evidence is published on Reynolds syndrome.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.